News | Breast Imaging | March 23, 2021

FDA Clears for ProFound AI Version 3.0 for 3D Mammography

Company’s third generation AI solution offers significant improvement in algorithm specificity performance and faster processing compared to previous versions of the software

 iCad announced that ProFound AI Version 3.0 for Digital Breast Tomosynthesis (DBT) was cleared by the U.S. Food and Drug Administration (FDA).

March 23, 2021 — iCad announced that ProFound AI Version 3.0 for Digital Breast Tomosynthesis (DBT) was cleared by the U.S. Food and Drug Administration (FDA). Compared to previous versions of the software, the ProFound AI 3.0 algorithm offers up to a 10% improvement in specificity performance and up to 1% improvement in sensitivity.[i] ProFound AI Version 3.0 also offers up to 40% faster processing on the new PowerLook platform.

“The FDA Clearance of ProFound AI Version 3.0 is yet another milestone that positions iCAD and our technology as vanguards in the cancer detection realm. Our third generation AI solution for DBT may afford physicians the ability to interpret an increasing amount of data in DBT cases and analyze each image to detect malignant lesions more efficiently and with even greater precision,” said Michael Klein, Chairman and CEO of iCAD. “Improvements in specificity, which correlates with reductions in false positives, typically come at the expense of sensitivity and cancer detection scores. To increase sensitivity while simultaneously improving specificity is a huge performance achievement.”

ProFound AI for DBT is a high-performance, deep-learning, workflow solution trained to detect malignant soft tissue densities and calcifications. It became the first 3D tomosynthesis software using artificial intelligence (AI) to be FDA cleared in December 2018.

Built with the latest in deep-learning technology, ProFound AI for DBT rapidly analyzes each tomosynthesis image, detecting malignant soft tissue densities. Certainty of Finding and Case Scores are relative scores computed by the ProFound AI algorithm and represent its confidence that a detection or case is malignant. The Certainty of Finding scores help radiologists by aiding in clinical decision making. Case Scores, which are assigned to each case by the algorithm, help clinicians to gain a sense of case complexity, which may be useful for prioritizing the reading work list.

“Late last year we made the decision to go enterprise-wide with ProFound AI,” said Alexander Sardiña, M.D., Chief Medical Officer for Solis Mammography. “From a patient perspective, improved specificity and sensitivity means that we can minimize the anxiety caused by false positives and recalls, without compromising cancer detection rates. This is a significant achievement. We’re excited to put this technology to work – on behalf of our patients – across our national network of facilities.”

In a reader study published in Radiology: Artificial Intelligence, ProFound AI for DBT Version 2.0 was shown to offer clinically proven time-savings benefits to radiologists, reducing reading time by 52.7 percent, improving radiologist sensitivity by 8 percent, and reducing false positives and unnecessary patient recall rates by 7.2 percent.[ii]

iCAD’s Breast Health Solutions suite also includes ProFound AI for 2D Mammography, ProFound AI Risk, the world’s first and only clinical decision support tool that provides an accurate two-year, breast cancer risk estimation that is truly personalized for each woman, based only on a screening mammogram,[iii] and software to evaluate breast density.

For more information: www.icadmed.com


[i] *iCAD data on file. Standalone performance varies by vendor. FDA Cleared.

[ii] Conant, E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1 (4). Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096

[iii] Eriksson M, Czene K, Strand F, et al. Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening. [published online ahead of print September 8, 2020]. Radiology. Accessed via https://doi.org/10.1148/radiol.2020201620

Related Content

A doctor reading #CXR scans using #SenseCare-Chest #DR Pro #diagnostic #software.

A doctor reading CXR scans using SenseCare-Chest DR Pro diagnostic software.

News | Artificial Intelligence | April 14, 2021
April 14, 2021 — SenseTime, a world-leading...
Comparisons of high definition and standard definition infrared imaging for digital histopathology. Image courtesy of the Beckman Institute

Comparisons of high definition and standard definition infrared imaging for digital histopathology. Image courtesy of the Beckman Institute

News | Breast Imaging | April 14, 2021
April 14, 2021 — Detecting and analyzing breast cancer
The U.S. Food and Drug Administration (#FDA) authorized marketing of #Medtronic's #GIGenius, the first device that uses #artificialintelligence (#AI) based on #machinelearning to assist #clinicians in detecting #lesions (such as #polyps or suspected tumors) in the #colon in real time during a c#olonoscopy.

The GI Genius intelligent endoscopy module works in real-time, automatically identifying and marking (with a green box) abnormalities consistent with colorectal polyps, including small flat polyps.

News | Artificial Intelligence | April 12, 2021
A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Image used with permission of RSNA.

A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Read more about this case study. Image used with permission of RSNA.

Feature | Coronavirus (COVID-19) | April 09, 2021 | By Dave Fornell, Editor
While the mass COVID-19 vaccinat
3-D mammography reduces the number of breast cancer cases diagnosed in the period between routine screenings, when compared with traditional mammography, according to a large study from Lund University in Sweden. The results are published in the journal Radiology.

Getty Images

News | Breast Imaging | April 09, 2021
April 9, 2021 — 3-D mammography reduces the number of breast cancer cases diagnosed in the period between routine scr
Varian announced it is collaborating with Google Cloud to build an advanced artificial intelligence (AI) based diagnostic platform to aid in the fight against cancer. Varian and Google Cloud AI embarked on a deployment journey, using Neural Architecture Search (NAS) technology via Google Cloud AI Platform, to create AI models for organ segmentation — a crucial and labor-intensive step in radiation oncology that can be a bottleneck in the cancer treatment clinical workflow.
News | Artificial Intelligence | April 08, 2021
April 8, 2021 — Varian announced it is collaborating with Google...
Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, announced today that it has signed a definitive agreement to be acquired by Hologic, Inc., a global leader in women's health, for an enterprise value of approximately $795 million.  This includes a cash payment of approximately $714 million for Mobidiag’s equity, and net debt of approximately $81 million.
News | Women's Health | April 08, 2021
April 8, 2021 — Mobidiag Oy, a privately held, commercial-stage F
Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

News | Artificial Intelligence | April 07, 2021
April 7, 2021 — Vysioneer, a leader in a...
Ultrasound is an invaluable diagnostic tool for the early detection of breast cancer, but the classification of lesions is sometimes challenging and time consuming. Could artificial intelligence hold the answer to solving these problems? Graphic courtesy of Chinese Medical Journal

Ultrasound is an invaluable diagnostic tool for the early detection of breast cancer, but the classification of lesions is sometimes challenging and time consuming. Could artificial intelligence hold the answer to solving these problems? Graphic courtesy of Chinese Medical Journal

News | Artificial Intelligence | April 06, 2021
April 6, 2021 — In 2020, the International Agency for Research on...